This program is supported by an independent education grant from Pfizer. This online education program has been designed solely for healthcare professionals in the US. The content is not intended for healthcare professionals in any other country.

Credits: AMA PRA Category 1 Credits™ (0.25.00 hours)

Type of activity: Enduring material (On-demand)

Launch date: 17 August 2026

Expiration date: 4 December 2027

Estimated time to complete this activity: 15 minutes

Join leading breast cancer expert Dr. Seth Wander for this accredited online ASCO 2026 Highlights Masterclass.

This expert-led educational session explores the most practice-changing data presented at the 2026 ASCO Annual Meeting and what it means for the management of HER2-positive metastatic breast cancer (MBC). Focusing on first-line maintenance strategies, Dr. Wander will translate emerging clinical evidence into practical treatment decisions that can be implemented immediately in routine practice.

Participants will gain actionable insights into optimizing treatment selection and sequencing, integrating endocrine therapy for patients with HER2+/HR+ disease, interpreting new efficacy and safety data, and proactively managing treatment-related toxicities to maintain therapy continuity and improve patient outcomes.

Session Overview

• ASCO 2026 Highlights: Review the most impactful HER2+ MBC data presented at ASCO and understand how these findings are shaping first-line maintenance strategies.
• Evidence into Practice: Learn how to apply emerging clinical evidence to personalize treatment selection, sequencing, transition to maintenance therapy, and endocrine integration for patients with HER2+/HR+ disease.
• Optimizing Long-Term Outcomes: Explore practical approaches to toxicity monitoring and management, enabling sustained treatment delivery while balancing efficacy, safety, and quality of life.

Prefer to read? Click here for the Key Clinical Summary.

Who Should Participate

This program is designed for healthcare professionals in the United States involved in the treatment and ongoing management of patients with HER2-positive metastatic breast cancer, including:

• Medical Oncologists
• Oncology Nurse Practitioners
• Oncology Physician Assistants
• Oncology Nurses

Faculty

Seth Wander, MD, PhD, is Director of Translational Research for the Breast Oncology Program at Massachusetts General Hospital, Director of Precision Medicine in the Termeer Center for Targeted Therapies, and Assistant Professor of Medicine at Harvard Medical School. A medical oncologist and translational researcher specializing in breast cancer genomics and precision medicine, his research focuses on treatment resistance and the development of personalized cancer therapies. Dr. Wander has received numerous honors, including the Dana-Farber Cancer Institute Wong Family Translational Research Award and the Conquer Cancer Foundation/American Society of Clinical Oncology Young Investigator Award.

Continuing Education Information

Commercial support: This activity received monetary support through an independent education grant from MSD.

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Faculty Disclosure Statement / Conflict of Interest:

Seth Wander, MD has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Consulting or Advisory Role: Arvinas, AstraZeneca, Biovica, Boundless Bio, Celcuity, Foundation Medicine, Genentech/Roche, Gilead Sciences, Halda Therapeutics, Hologic, Lilly, Novartis, Pfizer, Precede Bio, Puma Biotechnology, Regor Therapeutics, Stemline Therapeutics, Veracyte Speakers’ Bureau: 2nd.MD, Guardant Health, Lilly Research Funding: Arvinas, Genentech, Lilly, Nuvation Bio, Pfizer, Phoenix Molecular Designs, Puma Biotechnology, Regor Therapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible companies.

All relevant financial relationships for anyone involved with the content of this activity have been mitigated prior to the commencement of the program.

Activity Accreditation for Health Professions

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

• When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
• Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.

Participation Costs

There is no cost to participate in this program.

To Earn CME Credit:

1. Review the program materials

2. Click the green button on the right to "Claim CME credit"

3. Complete the Post-Test; this test features real-time learning. You will receive immediate feedback and rationales explaining the correct answers as you go. The requirement is 70% accuracy.

4. Once you have successfully passed the test and completed the required CME evaluation, your certificate will be available for download and emailed to you.

Disclaimer

This activity is intended for educational purposes only and does not establish a standard of care or replace clinical judgment. Any therapeutic or diagnostic strategies discussed must be evaluated in the context of each patient’s clinical circumstances, risks, and current evidence.

Learners should consult authoritative clinical guidelines and approved product information when considering treatment decisions.

All materials are used with permission. The views expressed are those of the faculty and do not necessarily reflect those of the accredited providers, MedAll, or any supporters.

Content is accurate as of the date of release.